AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7591530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 2180105 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone 40 mg per day for two weeks
Number of subjects: 127
Study 2180105 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate 500 micrograms thrice daily for two weeks
Number of subjects: 127
Study 2180105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 6110436 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline 10 or 20 mg sublingually 30 min before the meal
Number of subjects: 24
Study 6110436 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 4 mg four times daily for 1 week
Number of subjects: 24
Study 6110436 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 40 mg four times daily for 1 week (after isoprenaline)
Number of subjects: 24
Study 6110436 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg four times daily for 1 week (alone)
Number of subjects: 24
Study 6401954 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium cromoglycate, 1600 mg daily
Number of subjects: 24
Study 6401954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30734679 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum MTHFR levels (first quintile)
Number of subjects: 395
Study 30734679 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum MTHFR levels (second quintile)
Number of subjects: 395
Study 30734679 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum MTHFR levels (fourth quintile)
Number of subjects: 395
Study 30734679 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum MTHFR levels (fifth quintile)
Number of subjects: 395
Study 30734679 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR quintiles added to a model with conventional risk factors
Number of subjects: 395
Study 29541927 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy (PE)
Number of subjects: 200
Study 29541927 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment choice (choice vs no-choice)
Number of subjects: 200
Study 29541927 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment preference (preferred vs non-preferred)
Number of subjects: 200
Study 29541927 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy with sertraline (SER)
Number of subjects: 200
Study 26514581 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral THC
Number of subjects: 15
Study 26514581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 24582372 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined transcranial direct current stimulation (tDCS) and peripheral electrical stimulation (PES)
Number of subjects: 16
Study 24582372 — intervention group
Group type: COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) alone
Number of subjects: 16
Study 24582372 — intervention group
Group type: COMPARATOR
Intervention: Peripheral electrical stimulation (PES) alone
Number of subjects: 16
Study 24582372 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 16
Study 22841969 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Number of subjects: 53
Study 22841969 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 20352261 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-octylcyanoacrylate (2-OCA)
Number of subjects: 74
Study 20352261 — intervention group
Group type: COMPARATOR
Intervention: Skin staples
Number of subjects: 74
Study 18046054 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO gel
Number of subjects: 7
Study 18046054 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 7
Study 16082279 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC-LC (omeprazole, amoxicillin, clarithromycin for 7 days supplemented with fermented milk containing L. casei DN-114 001 for 14 days)
Number of subjects: 86
Study 16082279 — intervention group
Group type: COMPARATOR
Intervention: OAC (omeprazole, amoxicillin, and clarithromycin for 7 days)
Number of subjects: 86
Study 12171816 — intervention group
Group type: EXPERIMENTAL
Intervention: O2‐C (conventional oxygen cylinder)
Number of subjects: 10
Study 12171816 — intervention group
Group type: EXPERIMENTAL
Intervention: O2‐HF (refilled oxygen cylinders)
Number of subjects: 10
Study 12171816 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 10
Study 12171816 — intervention group
Group type: EXPERIMENTAL
Intervention: O2‐HFs
Number of subjects: 10
Study 12171816 — intervention group
Group type: EXPERIMENTAL
Intervention: O2‐C and O2‐HF
Number of subjects: 10
Study 10211146 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5‐20 mg)
Number of subjects: 300
Study 10211146 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (5‐20 mg)
Number of subjects: 300
Study 7796655 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention
Number of subjects: 577
Study 7796655 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 577
Study 7796655 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise intervention
Number of subjects: 577
Study 7796655 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 577
Study 2196085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) at 2.5 mg/kg/day
Number of subjects: 563
Study 2196085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) at 5 mg/kg/day
Number of subjects: 563
Study 2196085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA)
Number of subjects: 563
Study 2196085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 563
Study 2196085 — intervention group
Group type: COMPARATOR
Intervention: Etretinate
Number of subjects: 563
Study 314234 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 51
Study 314234 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 51
Study 31884318 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based focused attention training (MBAT)
Number of subjects: 78
Study 31884318 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation training (PMR)
Number of subjects: 78
Study 31884318 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MBAT and PMR)
Number of subjects: 78
Study 31155138 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 53
Study 31155138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 28770893 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity Repetition Training with Salat (prayer)
Number of subjects: 32
Study 28770893 — intervention group
Group type: COMPARATOR
Intervention: Task Oriented Training
Number of subjects: 32
Study 27421262 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based home care (HBHC)
Number of subjects: 60
Study 27421262 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based care
Number of subjects: 60
Study 25394949 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation program (individualized exercise program including pelvic floor muscle strengthening instructions and a healthy lifestyle guide)
Number of subjects: 100
Study 25394949 — intervention group
Group type: COMPARATOR
Intervention: Usual care (same pelvic floor muscle strengthening instructions and healthy lifestyle guide only)
Number of subjects: 100
Study 22569488 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation (SM)
Number of subjects: 210
Study 22569488 — intervention group
Group type: COMPARATOR
Intervention: Back School (BS)
Number of subjects: 210
Study 22569488 — intervention group
Group type: COMPARATOR
Intervention: Individual Physiotherapy (IP)
Number of subjects: 210
Study 19337010 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 (BIAsp30) + metformin (met)
Number of subjects: 50
Study 19337010 — intervention group
Group type: COMPARATOR
Intervention: Premixed human insulin 30/70 (BHI30) + metformin (met)
Number of subjects: 50
Study 17261662 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 10001
Study 17261662 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/d
Number of subjects: 10001
Study 17261662 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d (in patients with a history of HF)
Number of subjects: 10001
Study 17261662 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/d (in patients with a history of HF)
Number of subjects: 10001
Study 17261662 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d (in patients without a history of HF)
Number of subjects: 10001
Study 17261662 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/d (in patients without a history of HF)
Number of subjects: 10001
Study 15289727 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose daily chemotherapy (50 mg carboplatin and 50 mg etoposide)
Number of subjects: 301
Study 15289727 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily chemotherapy (30 mg carboplatin and 30 mg etoposide) with weekend chemotherapy (100 mg of each on Saturdays and Sundays)
Number of subjects: 301
Study 15289727 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hyperfractionated radiation therapy (69.6 Gy) with concurrent chemotherapy
Number of subjects: 301
Study 15289727 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend chemotherapy group
Number of subjects: 301
Study 11318298 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 2% eye drops
Number of subjects: 16
Study 11318298 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 16
Study 9815660 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 8306241 — intervention group
Group type: EXPERIMENTAL
Intervention: I.M. clonazepam (1 to 2 mg)
Number of subjects: 16
Study 8306241 — intervention group
Group type: COMPARATOR
Intervention: I.M. haloperidol (5 to 10 mg)
Number of subjects: 16
Study 3102056 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan (8 mg/m2 orally for 4 days)
Number of subjects: 205
Study 3102056 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan (6 mg/m2 for 4 days) and hexamethylmelamine (120 mg/m2 for 14 days) every 4 weeks
Number of subjects: 205
Study 31077799 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cycling exercise (12 min, 15 s work - 15 s rest)
Number of subjects: 10
Study 31077799 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 10
Study 28068789 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning Video Program
Number of subjects: 360
Study 28068789 — intervention group
Group type: COMPARATOR
Intervention: Usual advance care planning practices
Number of subjects: 360
Study 24811085 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (630 nm, 28 mW, continuous wave, 60 s, 1.68 J)
Number of subjects: 31
Study 24811085 — intervention group
Group type: COMPARATOR
Intervention: Placebo application (laser simulation)
Number of subjects: 31
Study 23054042 — intervention group
Group type: EXPERIMENTAL
Intervention: Wisebag with online (events transmitted via cellular signal in real-time)
Number of subjects: 50
Study 23054042 — intervention group
Group type: EXPERIMENTAL
Intervention: Wisebag with offline (events stored in device memory)
Number of subjects: 50
Study 23054042 — intervention group
Group type: COMPARATOR
Intervention: Inactive 'dummy' devices
Number of subjects: 50
Study 21496138 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen 1 g
Number of subjects: 105
Study 21496138 — intervention group
Group type: COMPARATOR
Intervention: PO acetaminophen 1 g
Number of subjects: 105
Study 21496138 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 105
Study 21496138 — intervention group
Group type: COMPARATOR
Intervention: PO acetaminophen
Number of subjects: 105
Study 19491687 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based maintenance exercise with group training sessions every 2 weeks after an initial 8-week training program
Number of subjects: 66
Study 19491687 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study 19491687 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based maintenance exercise
Number of subjects: 66
Study 16316746 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALCAR) 500 mg b.i.d.
Number of subjects: 204
Study 16316746 — intervention group
Group type: COMPARATOR
Intervention: Amisulpride 50 mg u.i.d.
Number of subjects: 204
Study 16316746 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALCAR)
Number of subjects: 204
Study 16316746 — intervention group
Group type: COMPARATOR
Intervention: Amisulpride
Number of subjects: 204
Study 16316746 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALCAR) and Amisulpride
Number of subjects: 204
Study 15059192 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk with Lactobacillus paracasei‐33 (LP‐33), 2 x 10(9) colony‐forming units per bottle for 30 days
Number of subjects: 80
Study 15059192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (fermented milk without LP‐33)
Number of subjects: 80
Study 10848901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mometasone furoate 200 microgram
Number of subjects: 38
Study 10848901 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral montelukast 10 mg
Number of subjects: 38
Study 10848901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 8798046 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopentol (Imagopaque); 300 mg I/ml, injected at 2 ml/kg b.w. (max 100 ml)
Number of subjects: 89
Study 8798046 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate (Hexabrix); 320 mg I/ml, injected at 2 ml/kg b.w. (max 100 ml)
Number of subjects: 89
Study 8798046 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall quality of CT enhancement
Number of subjects: 89
Study 8798046 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events, blood pressure, heart rate changes
Number of subjects: 89
Study 1595851 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 1595851 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 40
Study 6748661 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/day of disulfiram
Number of subjects: 40
Study 6748661 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/day of disulfiram
Number of subjects: 40
Study 6748661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30944040 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 206
Study 30944040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 29028981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID for 8 weeks
Number of subjects: 593
Study 29028981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID for 52 weeks
Number of subjects: 593
Study 29028981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID for 52 weeks
Number of subjects: 593
Study 29028981 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 52 weeks
Number of subjects: 593
Study 26895021 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05089771
Number of subjects: 0
Study 26895021 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05150122
Number of subjects: 0
Study 26895021 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05186462
Number of subjects: 0
Study 26895021 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05241328
Number of subjects: 0
Study 25273653 — intervention group
Group type: EXPERIMENTAL
Intervention: 3S anastomosis group (80 cases, 3S jejunal interposition)
Number of subjects: 153
Study 25273653 — intervention group
Group type: COMPARATOR
Intervention: Traditional anastomosis group (73 cases, esophageal remnant gastric posterior wall anastomosis)
Number of subjects: 153
Study 22917452 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 2332
Study 22917452 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 2332
Study 20401662 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins alone (1 mg folic acid, 7.2 mg pyridoxine, 0.02 mg cyanocobalamin daily)
Number of subjects: 132
Study 20401662 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants alone (150 mg ascorbic acid, 67 mg vitamin E, 9 mg β-carotene daily)
Number of subjects: 132
Study 20401662 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins with antioxidant vitamins
Number of subjects: 132
Study 20401662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 18556882 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 0
Study 15979810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alcohol infusion (0.2 g/kg)
Number of subjects: 26
Study 15979810 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 26
Study 12103284 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous suturing method
Number of subjects: 1542
Study 12103284 — intervention group
Group type: COMPARATOR
Intervention: Interrupted suturing method
Number of subjects: 1542
Study 12103284 — intervention group
Group type: EXPERIMENTAL
Intervention: More rapidly absorbed polyglactin 910 suture material
Number of subjects: 1542
Study 12103284 — intervention group
Group type: COMPARATOR
Intervention: Standard polyglactin 910 suture material
Number of subjects: 1542
Study 10404829 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-2 infusion at a rate of 0.8 pmol/kg x min
Number of subjects: 8
Study 10404829 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 8
Study 7563322 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasless laparoscopy‐assisted nephrectomy
Number of subjects: 7
Study 7563322 — intervention group
Group type: COMPARATOR
Intervention: Open nephrectomy
Number of subjects: 7
Study 1431013 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg single doses)
Number of subjects: 0
Study 1431013 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (therapeutic doses)
Number of subjects: 0
Study 3882004 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 8
Study 3882004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30261799 — intervention group
Group type: EXPERIMENTAL
Intervention: Egalitarian/fair female authority
Number of subjects: 342
Study 30261799 — intervention group
Group type: COMPARATOR
Intervention: Absolute male authority
Number of subjects: 342
Study 30261799 — intervention group
Group type: COMPARATOR
Intervention: Higher male authority
Number of subjects: 342
Study 31374985 — intervention group
Group type: EXPERIMENTAL
Intervention: SUCROSE (50 g sucrose)
Number of subjects: 11
Study 31374985 — intervention group
Group type: EXPERIMENTAL
Intervention: MALT (120 mg sucralose matched with 50 g maltodextrin)
Number of subjects: 11
Study 31374985 — intervention group
Group type: COMPARATOR
Intervention: NNS (120 mg sucralose)
Number of subjects: 11
Study 31374985 — intervention group
Group type: EXPERIMENTAL
Intervention: SUCROSE
Number of subjects: 11
Study 31374985 — intervention group
Group type: EXPERIMENTAL
Intervention: MALT
Number of subjects: 11
Study 31374985 — intervention group
Group type: COMPARATOR
Intervention: NNS
Number of subjects: 11
Study 29339723 — intervention group
Group type: EXPERIMENTAL
Intervention: fasoracetam (NFC-1) 400 mg BID for 4 weeks
Number of subjects: 30
Study 29339723 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 27121662 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Enhancement of Meaningful Activity (DEMA) intervention
Number of subjects: 36
Study 27121662 — intervention group
Group type: COMPARATOR
Intervention: Information Support (IS) control group
Number of subjects: 36
Study 21802266 — intervention group
Group type: COMPARATOR
Intervention: High-mucilage dose (HM)
Number of subjects: 18
Study 21802266 — intervention group
Group type: COMPARATOR
Intervention: Low-mucilage dose (LM)
Number of subjects: 18
Study 21765273 — intervention group
Group type: EXPERIMENTAL
Intervention: modified constraint‐induced movement therapy (mCIMT)
Number of subjects: 105
Study 21765273 — intervention group
Group type: EXPERIMENTAL
Intervention: bimanual intensive rehabilitation treatment (IRP)
Number of subjects: 105
Study 21765273 — intervention group
Group type: COMPARATOR
Intervention: standard treatment (ST)
Number of subjects: 105
Study 19820600 — intervention group
Group type: EXPERIMENTAL
Intervention: ORIF plus alpha-BSM (n = 24)
Number of subjects: 47
Study 19820600 — intervention group
Group type: COMPARATOR
Intervention: ORIF alone (n = 28)
Number of subjects: 47
Study 16627509 — intervention group
Group type: EXPERIMENTAL
Intervention: Group sessions of standardised intervention programmes for atopic dermatitis once weekly for six weeks
Number of subjects: 446
Study 15113718 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast cereal fortified with 440 microg folic acid, 1.8 mg vitamin B-6, and 4.8 microg vitamin B-12 for 12 weeks
Number of subjects: 189
Study 15113718 — intervention group
Group type: COMPARATOR
Intervention: Placebo cereal
Number of subjects: 189
Study 11356801 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 16
Study 11356801 — intervention group
Group type: COMPARATOR
Intervention: Control stretching exercises
Number of subjects: 16
Study 9380321 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/day
Number of subjects: 193
Study 9380321 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 193
Study 9380321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 1331830 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg i.v. given once prior to chemotherapy
Number of subjects: 125
Study 1331830 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 160 micrograms/kg i.v. given once prior to chemotherapy
Number of subjects: 125